ArticleJournal of ophthalmic inflammation and infection2025
Ocular complications in psoriatic patients: a systematic review and meta-analysis.
Article in Journal of ophthalmic inflammation and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biologic therapy is associated with reduced ocular disease in psoriasis: a real-world study.Eye (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the prevalence of ocular findings in patients with psoriasis and compare the odds of developing these conditions between the psoriatic and control population through a systematic review and meta-analysis.
methodsA comprehensive literature search was conducted using PubMed, Embase, Cochrane, and Web of Science databases to identify studies reporting ocular findings in psoriasis patients. Inclusion criteria encompassed cross-sectional, case-control, cohort studies, case series, and case studies. Data extraction and quality assessment followed PRISMA guidelines. The Newcastle-Ottawa Scale evaluated the risk of bias. Heterogeneity was assessed using Cochran's Q-test and I² statistics, with a random-effects model applied where significant heterogeneity was present.
results30 studies comprising 131,687 patients (13,788 with psoriasis and 117,899 controls) were included. The relative likelihood of ocular findings in psoriasis patients showed to be increased in conjunctival hyperemia (OR = 7.38; 95% CI: 2.47-22.04), conjunctivitis (OR = 4.63; 95% CI: 1.42-15.08), dry eye (OR = 3.47; 95% CI: 2.06-5.83), and meibomian gland dysfunction (OR = 7.13; 95% CI: 2.14-23.72) compared to controls. In contrast, blepharitis, cataracts, episcleritis, glaucoma, pinguecula, pterygium, and uveitis did not differ significantly between the two groups.
conclusionsPsoriasis patients are at increased risk for certain ocular conditions, particularly conjunctival hyperemia, conjunctivitis, dry eye, and meibomian gland dysfunction. Further research is needed to understand the underlying mechanisms and to develop targeted management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.